Meissner et al. conducted a retrospective case series involving 25 patients, concluding that in cases where mpMRI and PSMA PET indicated a high suspicion of prostate cancer, it might be a viable option to forgo a prostate biopsy prior to radical prostatectomy in well-informed, carefully selected patients (Meissner et al. 2022). This evidence concerns the gene FOLH1 and prostate cancer.